Opinion
Video
Metastatic HER2+ Breast Cancer: Current Strategies and Ongoing Trials
Experts discuss the CLEOPATRA trial outcomes, taxane nuances, and evolving strategies in first-line treatment. They review practical considerations and ongoing trials and dive into the dynamic landscape of managing metastatic HER2+ breast cancer, anticipating transformative developments.
This is a video synopsis/summary of a Peer Exchange involving Joyce O’Shaughnessy, MD; Priyanka Sharma, MD; Claudine Isaacs, MD; Heather McArthur, MD; and Hope S. Rugo, MD, FASCO.
O’Shaughnessy and Rugo discuss the first-line treatment landscape for metastatic HER2-positive breast cancer, focusing on the CLEOPATRA trial’s impact. CLEOPATRA demonstrated significant improvements in progression-free survival and overall survival by adding pertuzumab to docetaxel and trastuzumab. The long-term follow-up, 8 years post treatment, maintains these benefits. McArthur emphasizes the practical use of paclitaxel versus docetaxel based on tolerability. The conversation touches on the challenges of managing de novo metastatic disease and the role of hormone therapy. Ongoing trials such as PATINA and PEARL are expected to provide further insights into optimizing treatment strategies. Isaacs highlights the importance of considering patients’ quality of life and discusses ongoing Translational Breast Cancer Research Consortium trials exploring treatment cessation for those on long-term maintenance therapy. The discussion sets the stage for understanding the evolving landscape and sequencing of treatments in patients with metastatic HER2-positive breast cancer.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.
